Merck and Singapore sign deal on COVID-19 antiviral pill – Reuters.com

People queue up outside a quick test centre to take their coronavirus disease (COVID-19) antigen rapid tests, in Singapore September 21, 2021. REUTERS/Edgar Su/
SINGAPORE, Oct 6 (Reuters) – Pharmaceutical company Merck (MRK.N) announced on Wednesday a supply and purchase agreement with Singapore that will ensure it access to its experimental oral COVID-19 antiviral drug, the latest Asian country aiming to get supplies.
The drug Molnupiravir is designed to introduce errors into the genetic code of the coronavirus and would be the first oral antiviral medication for COVID-19. Merck is seeking approval from the U.S. Food and Drug Administration for the pill.
Singapore’s health ministry confirmed the deal though it declined to comment on the number of doses it purchased, citing commercial sensitivities.
The ministry said molnupiravir would be available for use after Merck, also known as MSD Pharma in Singapore, submitted data to the Health Sciences Authority (HSA) and gets authorisation for use in Singapore.
"The addition of molnupiravir to our portfolio of COVID-19 therapeutics ensures that we have a range of treatment options for different patient groups," the ministry told Reuters in an email.
There is no molnupiravir clinical trial in Singapore, it added.
Australia has also bought the Merck pill, while Thailand, South Korea, Taiwan and Malaysia have been in talks to buy it. The Philippines hopes its trial of the pill would allow it access.
The rush to order the drug comes after data from interim clinical trials released on Friday indicated it could reduce by about 50% the likelihood of hospitalisation or death for patients at risk of severe COVID-19.
Singapore reported a record 3,486 new coronavirus cases on Tuesday as it deals with its biggest outbreak of the pandemic.
It has vaccinated 83% of its people against COVID-19.
Our Standards: The Thomson Reuters Trust Principles.
Sign up to our health newsletter to keep up with the latest healthcare trends and pharmaceutical news.
Subscribe to our newsletter to get all the news you need to start your day.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved

source

Leave a Comment

Your email address will not be published.

Shopping Cart